Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 3Phase NA 2Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Glioblastoma 8Lymphoma, Non-Hodgkin 6Lymphoma, Mantle-Cell 5Gliosarcoma 5Hodgkin Disease 4Central Nervous System Neoplasms 4Lymphoma, Follicular 3Oligodendroglioma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoma 2Brain Neoplasms 2Astrocytoma 2Uveal Melanoma 1Sezary Syndrome 1Plasmablastic Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Infections 1

Interventions

Rituximab 24Lenalidomide 12Cyclophosphamide 12fludarabine phosphate 10Peripheral Blood Stem Cell Transplantation 10Mycophenolic Acid 6Cyclosporine 6Whole-Body Irradiation 5Radiotherapy 5Filgrastim 5ibritumomab tiuxetan 4Indium 4Etoposide 4romidepsin 3Sirolimus 3Prednisone 3Pentostatin 3Methotrexate 3Melphalan 3In Situ Hybridization, Fluorescence 3Gene Expression Profiling 3Everolimus 3Busulfan 3Bortezomib 3Bendamustine Hydrochloride 3zanubrutinib 2venetoclax 2veltuzumab 2temsirolimus 2obinutuzumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, B-Cell, Marginal Zone × Carmustine × Clear all
NCT03583424 2025-05-14

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
19 enrolled 12 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡